Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.56 |
| ▸ | CDK1 | P06493 | 5/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426182 | 1.00 | CDK2 (0.56) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL27897027 | 0.86 | CDK2 (0.44) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL17615377 | 0.84 | CDK2 (0.50) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL19112004 | 0.84 | CDK2 (0.55) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL30331956 | 0.83 | ADORA2A (0.50) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL946328 | 0.83 | ADORA2A (0.50) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL2314138 | 0.83 | CDK1 (0.55) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL31707890 | 0.83 | CDK2 (0.49) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL756290 | 0.83 | CDK2 (0.71) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL3441256 | 0.83 | CDK2 (0.71) | CDK2CDK5CDK5R1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025018768-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 한양대학교 산학협력단 | 2025-01-23 | — | — | WO | disclosed |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | TAIZHOU EOC PHARMA CO., LTD (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1056745-A2 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999043676-A2 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5866702-A | Purine inhibitors of cyclin dependent kinase 2 | CV THERAPEUTICS, INCORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK2, CCNK, CDK1 | CDK2 1/4885CDK5 15/4885CDK5R1 52/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | CDK2 565/4885CDK5 433/4885CDK5R1 1363/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CDK2 1/4885CDK5 19/4885CDK5R1 48/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | CDK2 1/4885CDK5 19/4885CDK5R1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.